Evidence map›Paper›PMID 40949723›Full record

SynthesisJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques2025

A systematic review of real-world evidence on the clinical relevance, characterization, and utility of

Patrick Rodriguez, Emma Kikerkov, Nora Emmott, Christine Y Lu, Rachele M Hendricks-Sturrup

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Patrick RodriguezDuke-Robert J. Margolis, MD, Institute for Health Policy, Washington, DC, United States.
Emma KikerkovDuke-Robert J. Margolis, MD, Institute for Health Policy, Washington, DC, United States.
Nora EmmottDuke-Robert J. Margolis, MD, Institute for Health Policy, Washington, DC, United States.
Christine Y Lu *Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, United States.
Rachele M Hendricks-Sturrup *Duke-Robert J. Margolis, MD, Institute for Health Policy, Washington, DC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenomic (PGx) research investigates how an individual's genetic make-up impacts their drug metabolism. PGx testing can therefore inform therapeutic decision-making, especially as compelling evidence develops over time to substantiate its clinical and personal utility across a range of therapeutic areas. PGx biomarker

Indexed as

Cytochrome P-450 CYP2D6Pharmacogenomic TestingBiomarkersClinical RelevanceHumansPharmacogeneticsBiomarkersCytochrome P-450 CYP2D6biomarker testingclaims dataCYP2D6electronic health recordspharmacogenomicsprecision medicinereal‐world datareal‐world evidence

Identifiers

PMID40949723
PMCPMC12425829

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.